Conformational analysis and receptor docking of N-[(1S,2S)-3-(4- chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl) pyridin-2-yl]oxy}propanamide (taranabant, MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist

Journal of Medicinal Chemistry

Volumn 51, Issue 7, 2008, Pages 2108-2114

  Lin, Linus S ^a   Ha, Sookhee ^a   Ball, Richard G ^a   Tsou, Nancy N ^a   Castonguay, Laurie A ^a   Doss, George A ^a   Fong, Tung M ^a   Shen, Chun Pyn ^a   Jing, Chen Xiao ^a   Goulet, Mark T ^a   Hagmann, William K ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDE; CANNABINOID 1 RECEPTOR AGONIST; HYDROGEN; HYDROXYL GROUP; RIMONABANT; TARANABANT;

ANIMAL CELL; ARTICLE; CONFORMATION; ENERGY; FEMALE; HUMAN; HYDROGEN BOND; MUTAGENESIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; RIGIDITY; X RAY CRYSTALLOGRAPHY;

AMIDES; AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; CELLS, CULTURED; CHO CELLS; COMPUTER SIMULATION; CRICETINAE; CRICETULUS; CRYSTALLOGRAPHY, X-RAY; HUMANS; HYDROGEN BONDING; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; MUTAGENESIS, SITE-DIRECTED; PYRIDINES; RECEPTOR, CANNABINOID, CB1; REFERENCE STANDARDS; SEQUENCE ALIGNMENT; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 41849121146     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm7014974     Document Type: Article

References (35)

1. (a) Greenberg, I.; Kuehnle, J.; Medelson, J.; Bernstein, J. Effects of marijuana use on body weight and caloric intake in humans. Psychopharmacology 1976, 49, 79-84.
2. (b) Trojniar, W.; Wise, R. A. Facilitory effect of Δ9- tetrahydrocannabinol on hypothalamically induced feeding. Psychopharmacology 1991, 103, 172-176.
3. (a) Arnone, M.; Maruani, J.; Chaperon, F.; Thiebot, M.; Poncelet, M.; Soubrie, P.; Le Fur, G. Selective inhibition of sucrose and ethanol intake by SR141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology 1997, 132, 104-106.
4. (b) Simiad, J.; Keane, M.; Keane, P. E.; Soubrie, P. SR141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behav. Pharmacol. 1998, 9, 179-181.
5. (c) Blundell, J. E.; Jebb, S. A.; Stiubbs, R. J.; Wilding, J. R.; Lawton, C. L.; Browning, L.; Whybrow, S.; Halford, J. C. G. Effect of rimonabant on energy intake, motivation to eat and body weight with or without hypocaloric diet: the REBA study. Obesity Rev. 2006, 7 (Suppl 2), 104-104.
6. (d) Stevens, C.; Cilissen, C.; Desmet, M.; et al. MK-0364, a CB1R inverse agonist, reduces acute food intake in overweight/obese male volunteers. Diabetes 2007, 56 (Suppl 1), A462.
7. (a) Liu, Y. L.; Connoley, I. P.; Wilson, C. A.; Stock, M. J. Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. Int. J. Obesity 2005, 29, 183-187.
8. (b) Addy, C.; Heymsfield, S.; Cilissen, C.; et al. MK-0364, a novel CB1R inverse agonist, increases energy expenditure in overweight and moderately obese subjects. Diabetes 2007, 56 (Suppl 1), A461.
9. (a) Colombo, G.; Agabio, R.; Diaz, G.; Lobina, C.; Reali, R.; Gessa, G. L. Appetite suppression and weight loss after the cannabinoid antagonist SR141716. Life Sci. 1998, 63, 113-117.
10. (b) Van Gaal, L. F.; Rissanen, A. M.; Scheen, A. J.; Ziegler, O.; Rossner, S. for the RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blockade rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005, 365, 1389-1397.
11. (a) For recent reviews, see: Antel, J.; Gregory, P. C.; Nordheim, U. CB1 cannabinoid receptor antagonists for treatment of obesity and prevention of comorbid metabolic disorders. J. Med. Chem. 2006, 49, 4008-4016.
12. 1 cannabinoid receptor antagonists. Drug Discovery Today 2005, 10, 693-702.
13. (a) Lin, L. S.; Lanza, T. J.; Jewell, J. P.; Liu, P.; Shah, S. K.; Qi, H.; Tong, X.; Wang, J.; Xu, S.; Fong, T. M.; Shen, C.-P.; Lao, J.; Chen, J.; Shearman, L. P.; Stribling, D. S.; Rosko, K.; Strack, A.; Marsh, D. J.; Feng, Y.; Kumar, S.; Samuel, K.; Yin, W.; Van der Ploeg, L.; Goulet, M. T.; Hagmann, W. K. Discovery of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3- cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy} propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity. J. Med. Chem. 2006, 49, 7584-7587.
14. (b) Chen, C.-y.; Frey, L. F.; Shultz, S.; Wallace, D. J.; Marcantonio, K.; Payack, J. F.; Vazquez, E.; Springfield, S. A.; Zhou, G.; Liu, P.; Kieczykowski, G. R.; Chen, A. M.; Phenix, B. D.; Singh, U.; Strine, J.; Izzo, B.; Krska, S. W. Catalytic, enantioselective synthesis of taranabant, a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity. Org. Process Res. Dev. 2007, 11, 616-623.
15. Fong, T. M.; Guan, X.-M.; Marsh, D. J.; Shen, C.-P.; Stribling, D S.; Rosko, K. M.; Lao, J.; Yu, H.; Feng, Y.; Xiao, J. C.; Van der Ploeg, L. H. T.; Goulet, M. T.; Hagmann, W. K.; Lin, L. S.; Lanza, T. J., Jr.; Jewell, J. P.; Liu, P.; Shah, S. K.; Qi, H.; Tong; X.; Wang, J.; Xu, S. S.; Francis, B.; Strack, A. M.; Macintyre, D. E.; Shearman, L. P. Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4- chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl) pyridin-2-yl]oxy}propanamide (MK-0364), in rodents. J. Pharmacol. Exp. Ther. 2007, 321, 1013-1022.
16. (a) Kapur, A.; Hurst, D. P.; Fleischer, D.; Whitnell, R.; Thakur, G. A.; Makriyannis, A.; Reggio, P. H.; Abood, M. E. Mutation studies of Ser7.39 and Ser2.60 in the human CB1 cannabinoid receptor: Evidence for a serine-induced bend in CB1 transmembrane helix 7. Mol. Pharmacol. 2007, 71, 1512-1524.
17. (b) Hurst, D.; Umejiego, U.; Lynch, D.; Seltzman, H.; Hyatt, S.; Roche, M.; McAllister, S.; Fleischer, D.; Kapur, A.; Abood, M.; Shi, S.; Jones, J.; Lewis, D.; Reggio, P. Biarylpyrazole inverse agonists at the cannabinoid CB1 receptor: Importance of the C-3 carboxamide oxygen/lysine3.28(192) interaction. J. Med. Chem. 2006, 49, 5969-5987.
18. (c) McAllister, S. D.; Rizvi, G.; Anavi-Goffer, S.; Hurst, D. P.; Barnett-Norris, J.; Lynch, D. L.; Reggio, P. H.; Abood, M. E. An aromatic microdomain at the cannabinoid CB(1) receptor constitutes an agonist/inverse agonist binding region. J. Med. Chem. 2003, 46, 5139-5152.
19. (d) Hurst, D. P.; Lynch, D. L.; Barnett-Norris, J.; Hyatt, S. M.; Seltzman, H. H.; Zhong, M.; Song, Z. H.; Nie, J.; Lewis, D.; Reggio, P. H. N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl) -4-methyl-1H-pyrazole-3-carboxamide (SR141716A) interaction with LYS3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor. Mol. Pharmacol. 2002, 62, 1274-1287.
20. (e) Salo, O. M. H.; Lahtela-Kakkonen, M.; Gynther, J.; Jarvinen, T.; Poso, A. Development of a 3D model for the human cannabinoid CB1 receptor. J. Med. Chem. 2004, 47, 3048-3057.
21. (f) Shen, C.-P.; Xiao, J. C.; Armstrong, H.; Hagmann, W. K.; Fong, T. M. F200A substitution in the third transmembrane helix of human cannabinoid CB1 receptor converts AM2233 from receptor agonist to inverse agonist. Eur. J. Pharmacol. 2006, 15, 41-46.
22. 1 cannabinoid receptor antagonists. J. Med. Chem. 2004, 47, 627-643.
23. Palczewski, K.; Kumasaka, T.; Hori, T.; Behnke, C. B.; Motoshima, H.; Fox, B. A.; Le Trong, I.; Teller, D. C.; Okada, T.; Stenkamp, R. E.; Yamamoto, M.; Miyano, M. Crystal structure of rhodopsin: A G protein-coupled receptor. Science 2000, 239, 739-745.
24. (a) Ballesteros, J.; Palczewski, K. G protein-coupled receptor drug discovery: Implications from the crystal structure of rhodopsin. Curr. Opin. Drug Discovery Dev. 2001, 4, 561-574.
25. (b) Baldwin, J. M.; Schertler, G. F.; Unger, V. M. An alpha-carbon template for the transmembrane helices in the rhodopsin family of G-protein-coupled receptors. J. Mol. Biol. 1997, 272, 144-164.
26. Shim, J.-Y.; Welsh, W. J.; Cartier, E.; Edwards, J. L.; Howlett, A. C. Molecular interaction of the antagonist N-(piperidin-1-yl)-5-(4- chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide with the CB1 cannabinoid receptor. J. Med. Chem. 2002, 45, 1447-1459.
27. Friesner, R. A.; Murphy, R. B.; Repasky, M. P.; Frye, L. L.; Greenwood, J. R.; Halgren, T. A.; Sanschagrin, P. C.; Mainz, D. T. Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J. Med. Chem. 2006, 49, 6177-6196.
28. (a) Sheldrick, G. M. Phase annealing in SHELX-90: Direct methods for larger structures. Acta Crystallogr. 1990, A46, 467-473.
29. (b) Sheldrick, G. M. SHELXL-97, Program for the refinement of crystal structures; Univ. of Göttingen, Germany.
30. CCDC 632855 contains the supplementary crystallographic data for this paper, which can be obtained free of charge from The Cambridge Crystallographic Data Centre via http://www.ccdc.cam.ac.uk/data_request/cif.
31. Annotated spectra are included in the Supporting Information.
32. Halgren, T. A. MMFF VII. Characterization of MMFF94, MMFF94s, and other widely available force fields for conformational energies and for intermolecular-interaction energies and geometries. J. Comput. Chem. 1999, 20, 730-748.
33. Underwood, D. J.; Sheridan, R. P.; Miller, M. D. Flexibases: A way to enhance the use of molecular docking methods. J. Comp.-Aided Mol. Des. 1994, 8, 565-582.
34. Labute, P. Chemical Computing Group Inc., MOE deployment strategies, http://www.chemcomp.com/software-pro.htm, accessed on Oct. 26, 2007.
35. Brooks, B. R.; Bruccoleri, R.; Olafson, B. D.; States, D. J.; Swaminathan, S.; Karplus, M. CHARMM: A program for macromolecular energy, minimization, and dynamics calculations. J. Comput. Chem. 1983, 4, 187-217.